Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease.
Prostaglandin E2 was administered to 22 newborns with ductus-dependent cyanotic congenital heart disease. Twelve patients had pulmonary atresia and ten simple dextrotransposition of the great arteries. Patients were classified into two groups: group 1 (n = 11) received prostaglandin E2 by the intravenous route (dose: 0.01-0.05 microgram/kg per min); group 2 (n = 11) received prostaglandin E2 by the oral route (dose: 35-65 micrograms/kg per 1-4 h). Treatment lasted for 1-90 days. All infants except one of group 2 showed a significant (greater than 10 Torr) increase in PaO2 following PGE2 administration. The mean increase in PaO2 was higher (P less than 0.01) in group 1 (21.8 +/- 1.7, Torr) than in group 2 (15.8 +/- 1.5, Torr). PaO2 fell significantly (P less than 0.01) in five patients of group 1 who continued treatment orally with satisfactory (greater than 30 Torr) levels in four of them. Severe side effects were observed only in group 1. The data show that similarly to prostaglandin E1 infusions, prostaglandin E2, given i.v. or orally, is useful in the management of infants with ductus-dependent cyanotic congenital heart disease. Oral prostaglandin E2, administration is less effective than i.v. infusions, but can be used for long-term, therapy being more convenient and causing minimal morbidity.
Thanopoulos
B D
BD
Andreou
A
A
Frimas
C
C
D000284:Administration, Oral; D015232:Dinoprostone; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007275:Injections, Intravenous; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use*; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D011664:Pulmonary Valve / Q000002:abnormalities*; D014188:Transposition of Great Vessels / Q000188:drug therapy*
D011458:Prostaglandins E; D011459:Prostaglandins E, Synthetic; D015232:Dinoprostone